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Abstract: Lysyl oxidases (LOX and LOX-likes (LOXLs) isoenzymes) belong to a family of
copper-dependent enzymes classically involved in the covalent cross-linking of collagen and elastin,
a pivotal process that ensures extracellular matrix (ECM) stability and provides the tensile and elastic
characteristics of connective tissues. Besides this structural role, in the last years, novel biological
properties have been attributed to these enzymes, which can critically influence cardiovascular
function. LOX and LOXLs control cell proliferation, migration, adhesion, differentiation, oxidative
stress, and transcriptional regulation and, thereby, their dysregulation has been linked to a myriad of
cardiovascular pathologies. Lysyl oxidase could modulate virtually all stages of the atherosclerotic
process, from endothelial dysfunction and plaque progression to calcification and rupture of advanced
and complicated plaques, and contributes to vascular stiffness in hypertension. The alteration of
LOX/LOXLs expression underlies the development of other vascular pathologies characterized by
a destructive remodeling of the ECM, such as aneurysm and artery dissections, and contributes
to the adverse myocardial remodeling and dysfunction in hypertension, myocardial infarction,
and obesity. This review examines the most recent advances in the study of LOX and LOXLs biology
and their pathophysiological role in cardiovascular diseases with special emphasis on their potential
as therapeutic targets.
Keywords: lysyl oxidases; cardiovascular diseases; atherosclerosis; aortic aneurysm; vascular
calcification; vascular stiffness; myocardial fibrosis
1. Introduction
Lysyl oxidase (LOX) is a copper-dependent enzyme which has been classically involved in the
oxidative deamination of specific ε-amino groups of lysine and hydroxylysine residues in collagen
and elastin, allowing the formation of highly reactive allysine aldehydes and producing hydrogen
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peroxide as by-product [1,2]. This reaction initiates the covalent cross-linking of collagen and elastin,
which is responsible for the tensile strength and elastic properties of connective tissues.
The LOX family is comprised of five closely related copper-dependent enzymes, LOX,
the archetypal member of this family, and four LOX-like isoenzymes (LOXL1, LOXL2, LOXL3,
and LOXL4) [3]. These enzymes share a conserved C-terminal region corresponding to the catalytic
domain, which consists of the lysine tyrosylquinone (LTQ) cofactor, the copper-binding site, and the
cytokine receptor-like domain. The N-terminal regions of these enzymes are structurally unrelated,
and their functions are undefined. LOX and LOXL1 contain a basic pro-peptide (PP) region,
while LOXL2, LOXL3, and LOXL4 possess four tandem repeats of the scavenger receptor cysteine-rich
(SRCR) domains, whose biological function remains unclear (Figure 1). LOX and LOXL1 are synthesized
and secreted into the extracellular space as inactive precursors. Then, they are proteolytically processed
by bone morphogenetic protein-1 (BMP-1) and other procollagen C-proteinases yielding the catalytically
active LOX/LOXL1 forms and their corresponding PPs, in a process in which other extracellular matrix
(ECM) components such as fibronectin also participate [4,5] (Figure 2). Whether LOXL2–4 could
require a proteolytic processing for their activation is currently unclear.
Biomolecules 2019, 9, 610 2 of 21 
The LOX family is comprised of five closely related copper-dependent enzymes, LOX, the 
archetypal member of this family, and four LOX-like isoenzymes (LOXL1, LOXL2, LOXL3, and 
LOXL4) [3]. These enzymes share a conserved C-terminal region corresponding to the catalytic 
domain, which consists of the lysine tyrosylquinone (LTQ) cofactor, the copper-binding site, and the 
cytokine receptor-like domain. The N-terminal regions of these enzymes are structurally unrelated, 
and their functions are undefined. LOX and LOXL1 contain a basic pro-peptide (PP) region, while 
LOXL2, LOXL3, and LOXL4 possess four tandem repeats of the scavenger receptor cysteine-rich 
(SRCR) domains, whose biological function remains unclear (Figure 1). LOX and LOXL1 are 
synthesized and secreted into the extracellular space as inactive precursors. Then, they are 
proteolytically processed by bone morphogenetic protein-1 (BMP-1) and other procollagen 
C-proteinases yielding the catalytically active LOX/LOXL1 forms and their corresponding PPs, in a 
process in which other extracellular matrix (ECM) components such as fibronectin also participate 
[4,5] (Figure 2). Whether LOXL2–4 could require a proteolytic processing for their activation is 
currently unclear. 
 
Figure 1. Schematic domain structure and homology of human LOX isoenzymes. The C-terminal 
regions of LOXs correspond to the highly conserved catalytic domain, which contains the copper 
binding motif and the lysyl tyrosyl quinone (LTQ) cofactor required for protein conformation and 
catalytic activity, respectively. Furthermore, the C-terminal domain contains the cytokine 
receptor-like (CRL) domain. LOX and LOXL1 pro-peptide regions and (Bone morphogenetic 
protein-1 (BMP-1) cleavage sites, which allow the proteolytic processing of these isoenzymes 
releasing the active forms, are indicated. The N-glycosylation sites in LOX pro-peptide are marked 
with diamonds. The four scavenger receptors cysteine rich (SRCR) domains contained by LOXLs 
isoenzymes in the N-terminal region are outlined. 
Figure 1. Schematic domain structure and homology of human LOX isoenzymes. The C-terminal
regions of LOXs correspond to the highly conserved catalytic domain, which contains the copper
binding motif and the lysyl tyrosyl quinone (LTQ) cofactor required for protein conformation and
catalytic activity, respectively. Furthermore, the C-terminal domain contains the cytokine receptor-like
(CRL) domain. LOX and LOXL1 pro-peptide regions and (Bone morphogenetic protein-1 (BMP-1)
cleavage sites, which allow the proteolytic processing of these isoenzymes releasing the active forms,
are indicated. The N-glycosylation sites in LOX pro-peptide are marked with diamonds. The four
scavenger receptors cysteine rich (SRCR) domains contained by LOXLs isoenzymes in the N-terminal
region are outlined.
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Figure 2. Biological functions and synthesis of LOX. LOX is synthesized as a pre-proenzyme which is 
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cleavage, copper incorporation, lysyl tyrosyl quinone (LTQ) formation, and glycosylation, the 
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mechanisms. Cytosolic LOX forms participate in the control of cell adhesion and motility in cancer 
cells, through a mechanism involving the H2O2-dependent activation of Src-kinase and the 
subsequent phosphorylation of focal adhesion kinase (FAK). Nuclear LOX regulates gene expression, 
at least in part, using histones H1/H2 as substrates. 
Beyond ECM maturation, in the last years novel biological functions have been ascribed to LOX 
and LOXLs (LOX/LOXLs), including the control of epithelial to mesenchymal transition, cell 
proliferation, migration, adhesion, transformation, and transcriptional regulation. Further, in view 
of the particular tissue expression patterns of LOX and LOXLs and the phenotypic differences of 
knockout animal models, it is considered that these isoenzymes would play different physiological 
roles and that they probably exhibit a dissimilar specificity of substrate. The existence of active 
intracellular LOX/LOXLs forms, in both the cytoplasm and nucleus, and the biological activity 
displayed by LOX-PP adds a further degree of complexity and hinders a better knowledge about the 
role of the LOX family on health and disease [2]. 
Dysregulation of LOX/LOXLs expression/activity has been linked to several human pathologies 
including cardiovascular diseases (Figure 3). LOX/LOXLs are expressed in the vascular wall and the 
heart, and the phenotype of genetically modified animal models for these enzymes support their 
critical contribution to cardiovascular function and development. LOX knockout mice, which die 
perinatally, show severe vascular abnormalities, characterized by the presence of aortic aneurysms, 
aortic tortuosity, extensive fragmentation of elastic fibers, morphological and adhesive alterations of 
endothelial cells, and discontinuities in the smooth muscle cell layer. LOXL1 deficiency is not lethal, 
but these animals also evidence vascular defects, although not as severe as those detected in LOX−/− 
mice [6]. Moreover, partial perinatal lethality is observed in LOXL2−/− mice associated with heart 
defects [7]. While no apparent alterations were detected in heart and aorta from LOXL3 knockout 
mice [8] and LOXL4−/− are not yet available, recent reports suggest their participation in vascular 
remodeling [9,10]. This review summarizes the current knowledge about the contribution of the 
Figure 2. Biological functions and synthesis of LOX. LOX is synthesized as a pre-proenzyme which is
post-translationally modified in endoplasmic reticulum (ER) and Golgi. After signal peptide cleavage,
copper incorporation, lysyl tyrosyl quinone (LTQ) formation, and glycosylation, the pro-LOX form is
released into the extracellular space. Then it is proteolyzed by bone morphogenetic protein (BMP-1)
yielding the mature catalytic LOX form, involved in extracellular matrix (ECM) stabilization, and its
pro-peptide, which exerts biological functions independently of LOX enzymatic activity. Extracellular
LOX could translocate into intracellular compartments by unknown mechanisms. Cytosolic LOX
forms participate in the control of cell adhesion and motility in cancer cells, through a mechanism
involving the H2O2-dependent activation of Src-kinase and the subsequent phosphorylation of focal
adhesion kinase (FAK). Nuclear LOX regulates gene expression, at least in part, using histones H1/H2
as substrates.
Beyond ECM maturation, in the last years novel biological functions have been ascribed to LOX and
LOXLs (LOX/LOXLs), including the control of epithelial to mesenchymal transition, cell proliferation,
migration, adhesion, transformation, and transcriptional regulation. Further, in view of the particular
tissue expression patterns of LOX and LOXLs and the phenotypic differences of knockout animal
models, it is considered that these isoenzymes would play different physiological roles and that they
probably exhibit a dissimilar specificity of substrate. The existence of active intracellular LOX/LOXLs
forms, in both the cytoplasm and nucleus, and the biological activity displayed by LOX-PP adds a
further degree of complexity and hinders a better knowledge about the role of the LOX family on
health and disease [2].
Dysregulation of LOX/LOXLs expression/activity has been linked to several human pathologies
including cardiovascular diseases (Figure 3). LOX/LOXLs are expressed in the vascular wall and the
heart, and the phenotype of genetically modified animal models for these enzymes support their
critical contribution to cardiovascular function and development. LOX knockout mice, which die
perinatally, show severe vascular abnormalities, characterized by the presence of aortic aneurysms,
aortic tortuosity, extensive fragmentation of elastic fibers, morphological and adhesive alterations of
endothelial cells, and discontinuities in the smooth muscle cell layer. LOXL1 deficiency is not lethal,
but these animals also evidence vascular defects, although not as severe as those detected in LOX−/−
mice [6]. Moreover, partial perinatal lethality is observed in LOXL2−/− mice associated with heart
defects [7]. While no apparent alterations were detected in heart and aorta from LOXL3 knockout
mice [8] and LOXL4−/− are not yet available, recent reports suggest their participation in vascular
remodeling [9,10]. This review summarizes the current knowledge about the contribution of the LOX
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family to cardiovascular diseases, the molecular mechanisms involved in, and discusses their potential
interest as pharmacological targets.
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2. Regulation of Vascular Homeostasis by LOX/LOXLs: Pathophysiological Impact
Different mechanisms link LOX virtually to all stages of the atherosclerotic process, from endothelial
dysfunction and plaque progression in the early stages, to calcification and rupture of advanced
and complicated plaques (Figure 4). LOX dysregulation seems also to be involved in other vascular
pathologies related with atherosclerosis, but mainly characterized by an intense destructuration of
ECM such as aneurysms and artery dissections.
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Figure 4. Putative effects of LOX/LOXLs disturbance on the onset and progression of
atherosclerosis. The indicated processes could be influenced by LOX/LOXLs dysregulation and
affect atherosclerosis progression.
2.1. Contribution to Arterial Aneurysms and Aortic Dissections
An aneurysm is a vascular abnormality characterized by the weakness and local dilation of the
arterial wall, defined as a 50% increase in the normal diameter of the vessel. Aortic aneurysms are the
most common form of this disease, a severe condition with high morbidity and mortality which can
lead to vascular rupture or dissection [11].
The potential involvement of LOX/LOXs in aortic aneurysm was already suggested in the 1990s,
when different experimental approaches in animal models supported the importance of LOX in the
maintenance of the mechanical stability of the aorta [12–14]. In fact, in rats, the irreversible inhibition
of LOX/LOXL activity with β-aminopropionitrile (BAPN) promoted aortic dilation [12]. Further,
the administration of BAPN to angiotensin II (Ang II)-infused ApoE knockout mouse, a classical
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model of aortic abdominal aneurysm (AAA), enhanced AAA incidence [15]. Interestingly, in two
other experimental models of AAA in rodents, the elastase- and the CaCl2-induced AAA models,
aneurysm development was accompanied by a reduction of LOX expression and activity [13,14].
It should be highlighted that local overexpression of LOX by aortic adenoviral delivery limited the
development of established CaCl2-induced AAA, at least in part by inhibiting vascular smooth muscle
cells (VSMC)-mediated MCP-1 secretion and JNK activity [14,16]. Similarly, in mice, genetic inactivation
of LOX, but not that of LOXLs, leads to aortic aneurysms and spontaneous dissections, supporting that
the inhibition of this specific isoenzyme could underlie the development of this disease [17,18].
Although experimental data support that LOX inhibition underlies AAA, in humans there is no
solid evidence showing a direct causal relationship between LOX/LOXLs and aortic aneurysms, probably
because human tissue specimens often come from late stages of aneurysmal disease. Considering
that AAA is a focal manifestation of a generalized vascular disturbance [19], LOX has been found
upregulated in a recent proteome analysis of internal mammary arteries from patients with AAA [20].
The authors consider the increase in LOX expression a compensatory response triggered by paracrine
or endocrine mechanisms to stabilize the aortic wall. Whether LOX activity/expression fails at early
stages of human AAA is difficult to assess because of the lack of vascular samples of these stages of
the disease.
Regarding thoracic aortic aneuryms (TAA), in 2016 two independent studies simultaneously
identified both a loss of function mutation and rare genetic variants in LOX predisposing to TAA [21,22].
Further, LOX protein levels were found downregulated in aortic dissections from ascending aorta
compared with healthy specimens [23], in agreement with a previous single case report study [24].
While defective LOX levels have been related to nonsyndromic aneurysms of ascending aorta,
enhanced LOX and LOXL1 expression and higher LOX activity have been reported in the aorta
from animal models and patients with Marfan syndrome, a systemic connective tissue disorder
characterized by severe cardiovascular manifestations, including TAA, acute aortic dissections,
and aortic ruptures [25]. The authors argue that the enhanced LOX-dependent collagen deposition
and cross-linking in this disease should be regarded as a compensatory response aiming to preserve
aortic integrity.
A reduction of vascular LOX expression has also been described in patients with cerebral
aneurysm and in experimental models of this disease, an effect associated with the high vascular levels
of interleukin-1β and the activation of NFkB signaling characteristics of this disorder [26]. A single
nucleotide polymorphism of LOXL2 has been associated with cerebral aneurysms [27], suggesting that
the inhibition of LOX/LOXLs could be a key event in the pathophysiology of this disease.
Therefore, aneurysmal diseases are associated with suppression of vascular LOX activity, while
experimental interventions or pathophysiological compensatory responses increasing LOX activity
seem to preserve artery integrity. Altogether, these data indicate that therapeutic approaches aiming to
normalize LOX activity could preserve the mechanical properties of the aortic wall and be a promising
strategy to limit the progression of different forms of vascular aneurysms.
2.2. LOX in Endothelial Dysfunction
LOX is highly expressed in the endothelium of healthy arteries [28], and multiple evidence
associates LOX downregulation with endothelial dysfunction. Indeed, endothelial LOX expression is
strongly inhibited by different conditions, which trigger endothelial dysfunction including high levels of
low-density lipoproteins (LDL) [29], hyperhomocysteinemia [30], and pro-inflammatory cytokines [31].
LDL increased the exchange of macromolecules across an endothelial monolayer, similarly to the
irreversible LOX inhibitor BAPN, suggesting that LOX downregulation by LDL could impair endothelial
barrier function [29]. The modulation of LOX by atherogenic concentrations of LDL operates both
in vitro and in vivo and has been observed in endothelial cells as well as in VSMC [28,29]. Although
the mechanism has not been characterized in detail, it seems to require the internalization of LDL by the
LDL receptor (LDLR) and the subsequent lysosome-mediated processing [28]. Hyperhomocystinemia,
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an atherosclerotic risk factor that induces endothelial dysfunction and alters the elastic properties
of the vascular wall, also inhibits LOX activity and negatively regulates endothelial LOX expression
at the transcriptional level [30]. The detrimental effects of homocysteine on LOX activity have
also been observed in small vessels in proliferative diabetic retinopathy [32]. The inhibition of
LOX by homocysteine depends on the thiol-group and the generation of reactive oxygen species
(ROS) [30]. Although the mechanism has not been further investigated in endothelial cells, in other
cell types it involves IL-6, Fli1, and epigenetic CpG methylation [33]. Likewise, pro-inflammatory
cytokines impair endothelial function and reduce LOX expression and activity both in vitro and
in vivo [31]. TNFα downregulation of LOX mRNA levels and enzymatic activity in endothelial cells
depends on TNFR2 and seems to be the consequence of a decrease in LOX transcriptional activity.
Interestingly, statins, lipid-lowering drugs widely used in the management of vascular diseases that
improve endothelial function, normalize vascular LOX down-regulation induced by TNFα in vitro
and by hypercholesterolaemia in vivo [34]. Although inducers of endothelial dysfunction commonly
downregulate LOX, in human endothelial cells LOX is upregulated by advanced glycation end
products (AGEs) via RAGE/MAPK signaling and NF-κB and AP-1, thereby impairing endothelial
homeostasis [35]. Taken together these results indicate that LOX dysregulation underlies endothelial
dysfunction elicited by cardiovascular risk factors.
2.3. LOX in Atherosclerosis Progression and Plaque Instability
The knowledge on the role of LOX in the onset, progression, and instability of atherosclerotic
plaque has been hampered by the lack of studies on this subject in humans, but different approaches in
animal models support the contribution of LOX in atherosclerosis.
In an early study conducted by Chvapil et al. [36] in very young chickens (1–2 days old) subjected
to a short feeding period with a cholesterol-rich diet, vascular LOX activity was not modified. However,
in the porcine model fed a high-fat diet (HFD) we observed that hypercholesterolemia downregulated
aortic LOX expression in the earliest stages of the atherosclerotic process (fatty streaks in the aorta
after 100 days of diet intervention) [29]. By contrast, in advanced atherosclerosis induced in rabbits fed
an atherogenic diet, LOX activity significantly increased, particularly in the aortic arch [37]. In aortic
atherosclerosis-prone regions of the ApoE-deficient (ApoE-KO) mice, the expression of LOX as well as
several genes encoding for ECM components, such as collagen I and fibronectin, were increased [38].
When these animals were switched to a HFD, despite the extraordinary high plasma cholesterol levels
reached, inhibition of LOX by the administration of BAPN reduced atherosclerotic lesion formation
(≈50%). Second harmonic generation 2-photon microscopy revealed reduction in structured collagen
in the neointima of lesions from BAPN-treated animals, with no changes in total collagen I [38].
Further, macrophage abundance in lesions was reduced by BAPN, an effect that was related to the low
adhesiveness of monocytes/macrophages to the ECM from these animals observed in vitro. Finally,
in a recent study, intense LOX immunostaining was located surrounding calcified areas in advanced
atherosclerotic lesions from humans [39] (see Section 2.5).
In complicated atherosclerotic plaques, LOX activity could impact on plaque stability. The stability
of the atherosclerotic plaque is preserved by the fibrous cap that overlies the lipid core. Acute clinical
complications, such as myocardial infarction, are usually caused by a thrombus formed on a vulnerable
plaque with a weakened fibrous cap that breaks. Fibrillar collagens synthesized by VSMC are the
main components of the fibrous cap, whose biomechanical properties and strength depends on the
cross-linking of collagen fibers [40]. In this regard, low LOX activity could lead to defective collagen
cross-linking, which would weaken the fibrous cap and favor the presence of soluble forms of collagen
highly susceptible to metalloproteinase degradation. In a recent study in atherosclerotic plaques
from human carotid endarterectomy specimens, LOX was strongly expressed in areas with ongoing
fibrogenesis, in the deeper layers of the fibrous cap and around the necrotic core enriched in CD163 +
macrophages (M2 macrophages with profibrotic and anti-inflammatory functions) [41]. In this study,
higher levels of LOX were detected in more stable plaques and, interestingly, high levels of LOX
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mRNA in carotid plaques were associated with a lower incidence of myocardial infarction during
the follow-up. Mediators of inflammation produced by activated macrophages, T cells, and other
inflammatory cells present in unstable plaques may control LOX expression and hence plaque stability.
Interferon γ (IFNγ), a cytokine involved in matrix remodeling and induced in ruptured atherosclerotic
plaques, reduces collagen I synthesis [42] and downregulates LOX in VSMC by both transcriptional and
post-transcriptional mechanisms [43]. Atherosclerotic lesions of mice with increased T-cell activation
shows reduced LOX expression and collagen cross-linking, probably due to the inhibition of LOX by
cytokines produced by activated T cells [44]. Conversely, in atherosclerosis-prone mice, osteoprotegerin
(OPG) promoted VSMC accumulation, LOX upregulation, LOX-dependent collagen fiber maturation,
and the formation of stable fibrous caps [45]. Therefore, LOX-dependent collagen cross-linking
could play a relevant role in limiting clinical complications by stabilizing atherosclerotic lesions and
preventing fibrous cap rupture. It should be taken in mind, however, that the modulation of LOX and
LOXLs such as LOXL2 by hypoxia [10,46] and their role in neovascularization, could also indirectly
affect plaque stability. Further, recent research has evidenced that mice overexpressing LOX in platelets
have more severe thrombosis supporting that LOX enhances platelet activation and thrombosis [47].
Specific studies to better establish the role of LOX/LOXLs in plaque instability are still needed.
2.4. LOX in VSMC, Vascular Remodeling, and Restenosis
VSMC plays a key role in vascular remodeling, a process which entails cell migration and
proliferation, as well as the production and reorganization of the ECM. LOX has been associated with
VSMC migration and proliferation and, as the isoform responsible for the 80% of the LOX activity in
aortic VSMC [48], is essential in ECM maturation.
Different growth factors and cytokines that activate VSMC and ECM synthesis increase LOX
expression. Transforming growth factor β (TGFβ) increases LOX expression and activity in VSMC [49]
and concomitantly enhances the synthesis of ECM components. Platelet derived growth factor (PDGF),
a key mitogen that promotes VSMC migration and proliferation and neointimal growth, also increases
LOX expression [50]. Both PDGF-BB and TGFβ are involved in the cross-talk between endothelial
and VSMC induced by low shear stress leading to LOX upregulation and vascular remodeling [51].
Further, LOX participates in vascular remodeling in HFD-fed rats and mediates the profibrotic effects
triggered by leptin-induced TGFβ in VSMC [52]. On the other hand, LOX binding to this cytokine
could suppress TGFβ signaling [53]. The vascular expression of LOX also seems to be highly dependent
on granulocyte macrophage colony-stimulating factor (GM-CSF). GM-CSF increases the expression
of both LOX and BMP-1 in VSMC, and GM-CSF-deficient mice exhibit low levels of LOX, BMP-1,
and tropoelastin, and impaired cross-linkage of elastic fibers [54].
In the past years, novel findings suggest that LOX/LOXLs functions extend beyond their role in
the stabilization of the ECM. Indeed, they markedly influence cell chemotactic responses, proliferation,
adhesion and migration [55], all of them cellular processes implicated in vascular remodeling.
It has been reported that LOX activity is essential to generate optimal chemotactic sensitivity of
VSMC to chemo-attractants by oxidizing specific cell surface proteins, such as PDGF receptor-β
(PDGFRβ) [56,57]. Concerning VSMC proliferation, mitogenic stimulation upregulates LOX in
rat adult VSMC [49], and a computational method identified LOX as a VSMC gene responsive to
proliferative stimulus [58]. In agreement, the expression of LOX and LOXLs increased in pathologies
characterized by intense VSMC migration and proliferation. LOX mRNA and protein expression
time-dependently increased after balloon injury of the rat carotid artery, preceding maximal collagen
accumulation and neointimal thickening [59]. In rabbits undergoing angioplasty, LOX inhibition
reduced restenotic rates and constrictive remodeling [60]. Further, all five LOX/LOLXs are dysregulated
in clinical and experimental pulmonary hypertension [10], a pathology characterized by increased
muscularization due to VSMC migration and proliferation, and perturbed matrix structures in the
vessel wall of small pulmonary arteries. However, other studies concluded that LOX restrains VSMC
proliferation. Indeed, an inverse correlation between LOX expression and neonatal VSMC proliferation
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has been reported [50]. LOX-PP also inhibited the proliferation of VSMC in culture, and was detected
at high levels in vascular lesions of injured arteries, suggesting that it could be part of a feedback
mechanism to limit vascular remodeling [61]. Recently, in a transgenic mouse which overexpresses
LOX in VSMC (TgLOXVSMC) we have shown that cell proliferation was significantly reduced in
TgLOXVSMC VSMC [62]. Transgenic VSMC also exhibited low levels of Myh10 (marker of SMC
phenotypic switching), PCNA (marker of cell proliferation), and MCP-1, and a reduced activation
of Akt and ERK1/2 in response to mitogenic stimuli (Figure 5A). Accordingly, neointimal thickening
induced by carotid artery ligation was attenuated in TgLOXVSMC mice (Figure 5C). In vivo and in vitro
studies ruled out any contribution of LOX-PP to the antiproliferative activity of LOX on VSMC and
evidenced the participation of extracellular and enzymatically active LOX forms [63].
Biomolecules 2019, 9, 610 8 of 21 
arteries, suggesting that it could be part of a feedback mechanism to limit vascular remodeling [61]. 
Recently, in a transgenic mouse which overexpresses LOX in VSMC (TgLOXVSMC) we have shown 
that cell proliferation was significantly reduced in TgLOXVSMC VSMC [62]. Transgenic VSMC also 
exhibited low levels of Myh10 (marker of SMC phenotypic switching), PCNA (marker of cell 
proliferation), and MCP-1, and a reduced activation of Akt and ERK1/2 in response to mitogenic 
stimuli (Figure 5A). Accordingly, neointimal thickening induced by carotid artery ligation was 
attenuated in TgLOXVSMC mice (Figure 5C). In vivo and in vitro studies ruled out any contribution of 
LOX-PP to the antiproliferative activity of LOX on VSMC and evidenced the participation of 
extracellular and enzymatically active LOX forms [63]. 
Finally, enzymatically active forms of LOX have been detected in the nucleus of VSMC [64,65]. 
The biological activity of nuclear LOX remains unraveled, but by affecting chromatin organization 
they could modulate gene expression, as has been shown for ECM components such as elastin and 
collagen [66–68], and VSMC proliferation [69]. 
 
Figure 5. LOX transgenesis limits VSMC proliferation and vascular remodeling. (A) 
Immunocytochemical analysis of LOX and PCNA, markers of cell proliferation, in aortic VSMC from 
TgLOXVSMC and WT mice. (B) Collagen type-I deposition (in red) by VSMC from TgLOXVSMC and WT 
mice visualized by confocal immunofluorescence in nonpermeabilized cells, as described [39]. Cells 
were incubated with a COL1A1 specific antibody (NB600-408; Novus Biologicals, UK) and nuclei 
were stained with DAPI. As observed, LOX transgenesis induces the deposition of a thicker and 
more organized collagen network (Bar: 25 µm). (C) TgLOXVSMC and WT mice were subjected to left 
common carotid artery ligation. Injured arteries were harvested 21 days after surgery, fixed in 4% 
paraformaldehyde, and embedded in paraffin. Cross-sections at 1.5 mm from the ligation site were 
stained with hematoxylin and eosin, as described [62,63]. This staining evidenced that LOX 
overexpression reduces neointimal growth (Bar: 100 µm). 
2.5. LOX in Vascular Calcification 
In the last decades, several epidemiological studies have demonstrated that vascular 
calcification is an independent predictor of cardiovascular events and all-cause mortality in the 
general population [70–72]. Vascular calcification is a complex and tightly organized biological 
process characterized by the deposition of calcium phosphate, the phenotypic transdifferentiation of 
vascular cells into osteo/chondroblast-like cells and an active remodeling of the ECM, which seems 
to play an active role in this process. Our recent investigations points towards LOX as a fundamental 
player in vascular mineralization. Using gain- and loss-of-function approaches we uncovered that 
Figure 5. LOX transgenesis limits VSMC proliferation and vascular remodeling. (A) Immunocytochemical
analysis of LOX and PCNA, markers of cell proliferation, in aortic VSMC from TgLOXVSMC and WT
mice. (B) Collagen type-I deposition (in red) by VSMC from TgLOXVSMC and WT mice visualized by
confocal immunofluorescence in nonpermeabilized cells, as described [39]. Cells were incubated with a
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Finally, enzymatically active forms of LOX have been detected in the nucleus of VSMC [64,65].
The biological activity of nuclear LOX remains unraveled, but by affecting chromatin organization
they could modulate gene expression, as has been shown for ECM components such as elastin and
collagen [66–68], and VSMC proliferation [69].
2.5. LOX in Vascular Calcification
In the last decades, several epidemiological studies have demonstrated that vascular calcification
is an independent predictor of cardiovascular events and all-cause mortality in the general
population [70–72]. Vascular calcification is a complex and tightly organized biological process
characterized by the deposition of calcium phosphate, the phenotypic transdifferentiation of vascular
cells into osteo/chondroblast-like cells and an active remodeling of the ECM, which seems to play an
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active role in this process. Our recent investigations points towards LOX as a fundamental player
in vascular mineralization. Using gain- and loss-of-function approaches we uncovered that LOX
contributes to the hyperphosphatemia (HPM)-induced calcification of VSMC and to VSMC-to-osteoblast
commitment [39]. In fact, HPM-induced VSMC calcification was accompanied by an up-regulation of
LOX expression in both human and murine VSMC. VSMCs isolated from TgLOXVSMC mice exhibited
an exacerbated HPM-induced calcium deposition and a higher increase in the expression of osteogenic
factors than wild-type cells. Similarly, in ex vivo studies on aortic rings from these animals exposed to
osteogenic media, we evidenced that LOX transgenesis was accompanied by enhanced deposition of
calcium. In line with the increased expression of LOX found in human VSMC cultured under osteogenic
conditions, we observed that HPM-induced mineralization was associated to a stronger deposition
of insoluble collagen [39], highlighting the importance of ECM quality on this process. Moreover,
pharmacological inhibition of LOX using BAPN (or LOX knockdown, by RNA interference) limited
calcium deposition and the upregulation of osteogenic factors induced by HPM in human VSMC.
In contrast with our data, the use of β-glycerophosphate as an inducer of VSMC calcification in bovine
VSMC promotes a downregulation of LOX, discrepancies which are probably due to species-specific
responses and disparities in the transduction pathways activated by each procalcifying stimulus [73].
Of note, in human atherosclerotic lesions we found a positive relationship between LOX expression
and calcium burden, and similarly enhanced LOX expression and collagen cross-linking have been
reported in human calcific aortic valve disease, supporting the pathophysiological relevance of our
results [39,74]. Considering that vascular calcification is a determinant factor of vascular stiffness,
our data evidence the critical involvement of LOX in both processes (see below).
2.6. LOXs, Vascular Stiffness, and Oxidative Stress: Impact on Hypertension
Vascular stiffening is a hallmark of vascular aging and pathological processes such as diabetes
atherosclerosis and hypertension. It has been established that vascular stiffness, measured as aortic
pulse wave velocity (aPWV), is an independent predictive factor of cardiovascular events both in
the general population and in subjects with other risk factors [75,76]. Therefore, the control of
vascular stiffness could be a promising strategy to ameliorate cardiovascular mortality, especially in
hypertension, because arterial stiffening itself has been proposed to be a causal factor in essential
hypertension [77].
Vascular stiffness is influenced, among other factors, by the structural elements of the arterial
wall, being collagen and elastin particularly determinants. Given the central role of LOX in collagen
and elastin cross-linking, we have recently assessed the contribution of LOX to vascular stiffness
and hypertension [78]. Mesenteric resistance arteries from TgLOXVSMC were stiffer than those from
control animals (Figure 6A). This effect was associated with a decrease in the number and size of
fenestrae in the internal elastic lamina (Figure 6B), alterations which have been previously associated
to the increased vascular stiffness in animal models of hypertension or during development [79].
The increased vascular stiffness and the disturbance on elastin structure found in TgLOXVSMC mice
were ameliorated by BAPN, indicating that these alterations are due to the enhanced vascular LOX
activity exhibited by these mice. Additionally, these animals showed an increased production of H2O2,
the by-product of LOX activity, along with a rise in vascular O2.− levels, NADPH oxidase activity,
NOX-1 expression, and mitochondrial dysfunction [78]. These results evidenced that LOX is a novel
source of vascular oxidative stress. It is worth mentioning that the LOX-induced production of ROS is
responsible for the enhanced vascular stiffness and the elastic alterations exhibited by LOX transgenic
mice, since these disturbances were attenuated by an H2O2 scavenger and a mitochondria-targeted
antioxidant [78].
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Figure 6. Contribution of LOX to oxidative stress and vascular stiffness in hypertension. (A) The
structural and mechanical properties of first-order mesenteric arteries were studied with a pressure
myograph (Danish Myo Tech, Aarhus, Denmark) as previously described [78,79]. Stress–strain curves
were obtained in arteries from WT and TgLOXVSMC mice. Vascular stiffness was determined from the
stress–strain relationship which is nonlinear; therefore, we obtained the incremental elastic modulus
(Einc) by determining the slope of the stress–strain curve of individual animals. Einc values were
(mean ± SEM) WT: 4.11 ± 0.12 (n = 6); LOX: 5.17 ± 0.27 (n = 8). *p < 0.05 vs. WT by unpaired
student t-test. For simplification, statistical analysis is shown in the stress–strain curves. (B) The
elastin organization within the internal elastic lamina was studied in segments of mesenteric arteries
from TgLOXVSMC and WT mice using fluorescence confocal microscopy based on the autofluorescent
properties of elastin (ex: 488 nm; em: 500–560 nm), as previously described [78,79]. Serial optical
sections from the adventitia to the lumen (z step = 0.5 µm) were captured with a X63 oil objective,
by using the 488 nm line of the confocal microscope. (image size 53 × 53 µm). (C) Working model
showing that LOX induced-oxidative stress alters elastin structure and promotes vascular stiffness
in hypertension.
It should be noted that although TgLOXVSMC mice are normotensive, their vascular alterations
resemble those from hypertensive models. In fact, our investigations also revealed that LOX is
upregulated in the vascular wall of two animal models of hypertension, the spontaneously hypertensive
rat (SHR) and Ang II-infused mice, and that the increase in vascular LOX levels results from the
hemodynamic effect induced by hypertension. More interestingly, the upregulation of LOX in
hypertension is partially responsible for the enhanced vascular stiffness and the higher production of
ROS from different sources found in these hypertensive models, as revealed in experiments in which
LOX activity was inhibited by BAPN. Likewise, BAPN also abolished the Ang II-induced activation
of p38MAPK, responsible for vascular stiffness in hypertension. In accordance, TgLOXVSMC mice
exhibit an activation of p38MAPK in the vessel wall, which relies on the higher vascular oxidative
stress of these animals, while the inhibition of this kinase limited stiffness and the alterations in elastin
structure [78]. Therefore, using complementary gain-of-function and LOX inhibition approaches,
we demonstrated that LOX up-regulation is associated with enhanced vascular oxidative stress,
which promotes p38MAPK activation, elastin structural alterations, and vascular stiffness in resistance
and conductance arteries in hypertension (Figure 6C).
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While our study was focused on elastin, both collagen and elastin cross-linking could contribute to
vascular stiffness in hypertension as has been suggested in Ang II-infused animals [80]. In fact, in Ang
II-infused mice, BAPN reduced vascular collagen content and cross-linking and vascular stiffness.
Then, we cannot discard that the higher vascular stiffness exhibited by TgLOXVSMC mice could be
associated with the enhanced deposition of mature collagen that we described in this animal model
(Figure 5B) [62]. In any case, our study provides novel information about the key role of LOX in elastin
deposition and vascular stiffness.
Although the participation of LOX in vascular stiffness is well demonstrated, its contribution to
high blood pressure is still unclear. TgLOXVSMC mice (at 3 months of age) show normal blood pressure,
and although BAPN partially prevented hypertension development in Ang II-infused mice, it was not
able to decrease high blood pressure in adult SHR with well-established hypertension [78]. Moreover,
newborn LOX-/- mice show normal blood pressure [81]. It is important to note that arterial stiffening is
not the unique determinant of hypertension, but many other mechanisms might operate, and therefore,
the contribution of LOX should be specifically addressed. Nevertheless, our results indicate that
limiting ECM cross-linkage could ameliorate vessel stiffness and improve the management of patients
with cardiovascular disorders.
Regarding other isoenzymes of this family, LOXL2 was identified as a candidate gene in a
genome-wide association study for blood pressure and arterial stiffness [82]. Indeed, this enzyme
has been recently involved in the regulation of age-associated vascular stiffness, since the increase
in PWV induced by aging was ameliorated in LOXL2+/− mice [83]. The authors demonstrated that
LOXL2 enhances VSMC stiffness and contractility and induces matrix deposition. These results are in
agreement with previous reports supporting that the intrinsic stiffening of VSMC also underlies the
enhanced aortic stiffness with aging [84]. Whether LOX and other LOXL isoenzymes are involved in
the control of intrinsic VSMC stiffening is an issue that deserves further research.
2.7. LOX and LOXLs in Neovascularization
Both LOX and LOXL2 have been positively involved in neovascularization, although most of the
approaches were focused on tumor angiogenesis. In endothelial cells, the expression of these enzymes
is induced by hypoxia, which is a potent angiogenic stimulus [46,85]. In fact, in models of pathological
and developmental neovascularization, LOXL2 was detected in angiogenic endothelial cells and
tip cells [85,86] and its knockdown in zebrafish embryos significantly suppressed intersegmental
vessel circulation. Gain- and loss-of-function studies in HUVEC and microvascular endothelial cells
evidenced that LOXL2 contributes to endothelial tube formation through the modulation of endothelial
cell migration and proliferation [85,87], and more importantly through collagen IV network assembly,
which seems to be critical for capillary formation [85]. It should be noted that in this study on cell
migration, tubulogenesis and collagen IV assembly were modestly affected by BAPN, and that a
catalytically inactive LOXL2 mutant triggered a similar increase in endothelial cell migration and
angiogenic sprouting than wild-type LOXL2. Thus, this suggests that the modulation of these processes
by LOXL2 only partially depends on its catalytic activity [85,87]. Indeed, it has been recently suggested
that LOXL2 might promote angiogenesis through the regulation of endothelial-to-mesenchymal
transition (EndMT) and the activation of PKB/AKT and FAK signaling pathways [87]. However,
the contribution of LOXL2 enzymatic activity could not be ruled out because a LOXL2 inhibitory
antibody (AB0023) ameliorated basic fibroblast growth factor (bFGF)-induced cell migration and
network assembly in HUVEC [88]. The expression of LOXL2 was also specifically induced in tumor
endothelial cells which LOXL2 blockade with AB0023 limited tumor vascularization [88,89]. Likewise,
small LOXL2 inhibitors decrease tumor angiogenesis and restrict tumor growth [90].
While LOXL2 has been involved in the angiogenic response of both normal and tumoral endothelial
cells, evidence regarding the contribution of LOX to neovascularization is weak and the studies were
mainly focused on tumor angiogenesis. Tumor-derived LOX drives angiogenesis through PDGFRβ
stimulation and AKT activation leading to an increased production of VEGF [91]. However, it should
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be noted, that this proangiogenic response was exerted by the LOX-induced production of VEGF
by tumor cells and that whether this mechanism could operate in vascular endothelial cells in an
autocrine manner was not evaluated. A subsequent study evidenced that LOX expression and activity
are sharply higher in tumor endothelial cells than in normal cells and that LOX knockdown limits
tumor endothelial cell motility and tubulogenesis through the inhibition of FAK signaling [92]. Further,
overexpression of both LOX and LOXL2 increased tumor perfused vessel density in different syngeneic
models [93]. In contrast, in a mouse model of breast cancer, while the number of tumor-associated
endothelial cells was reduced by the LOXL2 targeted antibody AB0023, microvessel density was
not significantly modulated by M64, a LOX-specific antibody raised against LOX catalytic domain,
supporting a major role of LOXL2 on tumor neovascularization [89].
A recent study reported that LOX-PP inhibits major angiogenic signaling pathways, attenuating
HUVEC proliferation, migration and adhesion, and reducing tubulogenesis in the chicken
chorioallantoic membrane assay [94]. Although high concentrations of LOX-PP were used in some
of these assays, in view of these data, further studies should be necessary to clarify the role of each
specific LOX form in physiological and pathological angiogenesis.
In the last years, exosomes raised as key signaling players in the cross-talk between different
cell types, as carriers of mRNAs, miRNAs, and proteins. It has been described that LOXL4 could
be delivered by hepatocellular carcinoma exosomes and transferred to endothelial cells promoting
angiogenesis [95]. Similarly, glioma cell-derived exosomes are internalized by endothelial cells.
Exosomes from glioma cells exposed to hypoxia were enriched in LOX and in other relevant proteins in
angiogenesis inducing microvascular sprouting. Whether the cargo of LOX in hypoxic exosomes could
actively contribute to their pro-angiogenic activity should be, however, clarified [96,97]. Based on
these studies and others reporting that LOXL2 levels were increased in endothelial cell-derived
exosomes from patients with atherosclerotic cerebrovascular disease, it is tempting to speculate that
exosome-derived LOX/LOXLs could have a relevant pathophysiological role in cardiovascular and
tumor diseases.
3. LOX and Heart Disease
Myocardial interstitial fibrosis is a hallmark of virtually all forms of heart disease, having
detrimental consequences on left ventricular (LV) function and actively contributing to the progression
of heart failure (HF), a leading cause of death in industrialized countries. Fibrosis, which
is a critical determinant of diastolic dysfunction and cardiac stiffness, is characterized by an
unbalance between synthesis and degradation of collagen, the major constituent of cardiac ECM.
Enhanced cardiac LOX/LOXLs expression/activity has been associated with the adverse myocardial
remodeling and dysfunction in animal models of hypertension, cardiac infarct, and obesity [52,98–100].
Interestingly, in the last years different studies in both hypertensive animal models and humans have
highlighted the importance of collagen quality beyond collagen amount negatively influencing heart
function [99,101–103]. In hypertensive patients with stage C chronic HF, elevated filling pressures
are associated with the degree of collagen cross-linking (but not with total collagen) which, in turn,
correlates with cardiac LOX expression and more importantly, with an impairment of systolic and
diastolic function [102]. In agreement, HF patients with normal ejection fraction showed enhanced
myocardial collagen content, but also increased LOX expression and collagen cross-linking, both
associated with diastolic dysfunction [103]. The relationship between LOX and diastolic function
was also evidenced in a recent study using a new LOX transgenic mouse model. This work shows
that myocardial LOX overexpression in mice is associated with an age-dependent disturbance of
diastolic function and an accelerated cardiac remodeling [104]. Interestingly, LOX transgenesis also
exacerbates Ang II-induced cardiac hypertrophy and systolic dysfunction, enhancing inflammation
and ROS production and altering Ang II-dependent signaling. Further, this study uncovers the
ability of LOX to promote fibroblast-to-myofibroblast transition, a critical process involved in cardiac
fibrosis and remodeling. Similarly, the expression of LOXL2 is increased in patients with ischemic
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or idiopathic dilated cardiomyopathy in which cardiac LOXL2 correlates with collagen cross-linking
and with the impairment of diastolic function [105]. Consistent with data described above for
LOX, LOXL2 also contributes to cardiac fibroblast reprogramming [105], highlighting the importance
of ECM stiffness and composition driving myofibroblast activation [106]. Therefore, these data
evidence that the upregulation of LOX/LOXLs in cardiac diseases not only passively contribute to
cardiac fibrosis, but actually implies that these enzymes are active players in cardiac dysfunction and
disease progression.
Mechanistically, most of the growth factors and cytokines involved in cardiac fibrosis could
contribute to the upregulation of LOX and LOXLs in the pathological myocardium. TGFβ, a critical
cytokine involved in cardiac fibrosis and remodeling, is an upstream regulator of LOX in cardiac
fibroblasts, inducing LOX expression through PI3K/Akt, Smad3, and MAPKs signaling pathways [107].
The enhanced Smad2/3 signaling triggered by TGFβ also increases c-jun expression which is the ultimate
responsible for the TGFβ-mediated activation of LOX transcription [108]. Concomitantly, this response
is associated to an enhanced expression of collagens I and III, and BMP-1, resulting in a greater fibrotic
response [107]. Similarly, inflammatory factors have been implicated in adverse cardiac remodeling
and fibrosis, including TNFα and osteopontin (OPN). Transgenic mice that overexpress TNF-α in
the myocardium develop cardiac hypertrophy, fibrosis, dilated diopathy, and premature death [109].
The profibrotic response triggered by TNFα in the myocardium involves the upregulation of LOX due
to a TNFα-dependent induction of TGFβ signaling [110]. In turn, OPN, a multifunctional cytokine
strongly expressed in the fibrotic myocardium, promotes fibroblast-to-myofibroblast transdifferentiation
and upregulates LOX in human fibroblasts. The authors suggest that OPN contributes myocardial
stiffness and dysfunction in patients with hypertensive heart disease and HF, at least in part, through
the upregulation of LOX and the consequent increase in collagen crosslinking [111]. Likewise, the
activation of the TH1 lymphocytic function in mice enhances myocardial LOX expression (LOX
and LOXL3) and activity and collagen crosslinking, thereby altering cardiac diastolic function [112].
Although significant efforts have been made to decipher the molecular mechanisms underlying the
enhanced ECM crosslinking and LOX/LOXLs expression in the diseased heart, further studies should
be addressed to clarify this issue.
Considering the negative impact of an excessive LOX/LOXL-mediated crosslinking of collagen on
cardiac function, pharmacological strategies targeting LOX/LOXLs raise as promising therapeutic tools
in patients with HF, as discussed below.
4. LOXs as Pharmacological Targets for Cardiovascular Diseases
As outlined in this review, the impact of LOX/LOXLs dysregulation on the cardiovascular system
and its contribution to different cardiovascular disorders support the interest of these enzymes as novel
pharmacological targets for these diseases. The development of LOX/LOXLs-targeted therapeutic
tools, however, has been hampered by the unavailability of their crystallographic structure and the fact
that both increases and decreases of LOX/LOXLs underlie the development of different cardiovascular
diseases that often coexist. Therefore, the therapeutic blockade or, when appropriate, the upregulation
of LOX/LOXLs must be thoroughly evaluated to ensure their safety.
The importance of collagen quality in heart performance and the impact of LOX/LOXLs on cardiac
fibroblast function highlight the interest of LOX/LOXLs-inhibitory therapies to slow HF progression and
limit the detrimental impact of cardiac remodeling in response to myocardial infarction [98,101–103].
Further, an excessive LOXs-dependent cross-linking could interfere with tissue drug distribution, as
demonstrated for chemoresistant tumors [93] and, therefore, limiting LOX-induced cardiac stiffness
could improve the therapeutic response to established therapies. However, chronic and irreversible
LOXs inhibition, such as that achieved by BAPN, might disturb the appropriated ECM scaffold
and compromise ventricular integrity. Similarly, although LOX inhibition could decrease vessel
stiffness and this might have beneficial effects to protect from cardiovascular events in hypertension,
chronic LOX/LOXLs blockade could promote plaque instability, while the risk of vascular aneurysm and
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dissection should not be ignored. It is clear that irreversible inhibitors of LOX/LOXLs, such as BAPN,
have enormous limitations as therapeutic tools for chronic use. In fact, it has been reported that chronic
administration of BAPN induces neurotoxicity and causes lathyrism, a disorder characterized by
connective tissue alterations which notably affects bone mechanical strength and blood vessels [113–116].
To avoid these drawbacks, monoclonal antibodies against LOX and LOXL2 have been developed
and proven effective in reducing cardiac fibrosis and dysfunction in experimental models of pressure
overload and myocardial infarct [98,105]. Simtuzumab, a humanized IgG4 monoclonal antibody against
LOXL2, has been tested for its antifibrotic capacity in patients with liver and lung fibrosis and pancreas
cancer [117]. However, these clinical trials fail to evidence the efficacy of simtuzumab as an antifibrotic
agent despite promising results in preclinical studies in animal models [117]. Whether simtuzumab
could provide positive results limiting cardiac fibrosis is currently unknown. Likewise, small molecules
that directly inhibit LOXL2 catalytic activity are being developed and tested into healthy volunteer
Phase 1 trials [118].
Beyond the development of specific LOX/LOXLs inhibitors, other strategies to reduce LOX activity
might involve the use of chelating agents, such as bathocuproine or polyamine chelators, which
limit the availability of copper required for the biogenesis of LTQ. Alternatively, BMP-1 inhibition,
which would limit the extracellular processing of LOX and LOXL1, could be an additional approach to
inhibit LOX.
Another issue to be considered is the potential impact on LOX activity of drugs in use for the
management of cardiovascular diseases. Current HF therapies such as torasemide reduced cardiac
LOX expression, collagen cross-linking, fibrosis, and LV stiffness in patients with hypertensive HF [119].
Similarly, EXP3179, a metabolite of losartan, reduced cardiac LOX expression and collagen cross-linking
in hypertensive rats [120], while, as described above, statins normalize endothelial LOX expression in
hyperlipemic animals [34].
5. Conclusions and Future Challenges
The experimental findings summarized in this review evidence the key contribution of LOX and
LOXLs to multiple aspects of cardiovascular homeostasis, which could be relevant for the development
of high-incidence human diseases such as atherosclerosis, HF, arterial aneurysms and aortic dissection.
Although significant advancements have been made, overall, the failure of clinical trials in analyzing
the antifibrotic properties of simtuzumab indicates the need of a deeper understanding of LOX/LOXLs
biology. It is mandatory to identify which are their specific intracellular and extracellular functions
and substrates, to develop novel methods allowing to assess the degree of LOX inhibition in the
targeted tissues and to identify those patients who will benefit by LOX/LOXLs-targeted therapy.
Because regulation of LOX activity could be a double-edged sword, safety concerns should be
seriously approached.
Author Contributions: All the authors contribute to the writing and/or revision of the manuscript.
Funding: The authors thank the support provided by the Spanish Ministerio de Ciencia, Innovación
y Universidades (MICIU), Instituto de Salud Carlos III (ISCIII) [grants RTI2018-094727-B-100, PI18/0919,]
and Agencia de Gestio d’Ajuts Universitaris i de Recerca (AGAUR; program of Support to Research Groups,
Ref. 2017-SGR-00333). Our studies were also co-founded by Fondo Europeo de Desarrollo Regional (FEDER),
a way to make Europe. L.C. and M.G. were supported by a FI fellowship (AGAUR) and the Miguel de Servet
Program (ISCIII; CP15/00126) respectively.
Acknowledgments: We apologize to all colleagues whose important contributions could not be cited due to
space limitations.
Conflicts of Interest: The authors declare no conflict of interest.
Biomolecules 2019, 9, 610 15 of 21
References
1. Rodríguez, C.; Martínez-González, J.; Raposo, B.; Alcudia, J.F.; Guadall, A.; Badimon, L. Regulation of lysyl
oxidase in vascular cells: Lysyl oxidase as a new player in cardiovascular diseases. Cardiovasc. Res. 2008,
79, 7–13. [CrossRef] [PubMed]
2. Kagan, H.M.; Li, W. Lysyl oxidase: Properties, specificity, and biological roles inside and outside of the Cell.
J. Cell Biochem. 2003, 88, 660–672. [CrossRef] [PubMed]
3. Molnar, J.; Fong, K.S.; He, Q.P.; Hayashi, K.; Kim, Y.; Fong, S.F.; Fogelgren, B.; Szauter, K.M.;
Mink, M.; Csiszar, K. Structural and functional diversity of lysyl oxidase and the LOX-like proteins.
Biochim. Biophys. Acta 2003, 1647, 220–224. [CrossRef]
4. Rodríguez, C.; Rodríguez-Sinovas, A.; Martínez-González, J. Lysyl oxidase as a potential therapeutic target.
Drug News Perspect. 2008, 21, 218–224. [CrossRef] [PubMed]
5. Fogelgren, B.; Polgár, N.; Szauter, K.M.; Ujfaludi, Z.; Laczkó, R.; Fong, K.S.; Csiszar, K. Cellular fibronectin
binds to lysyl oxidase with high affinity and is critical for its proteolytic activation. J. Biol. Chem. 2005, 280,
24690–24697. [CrossRef] [PubMed]
6. Liu, X.; Zhao, Y.; Gao, J.; Pawlyk, B.; Starcher, B.; Spencer, J.A.; Yanagisawa, H.; Zuo, J.; Li, T. Elastic fiber
homeostasis requires lysyl oxidase-like 1 protein. Nat. Genet. 2004, 36, 178–182. [CrossRef]
7. Martin, A.; Salvador, F.; Moreno-Bueno, G.; Floristán, A.; Ruiz-Herguido, C.; Cuevas, E.P.; Morales, S.;
Santos, V.; Csiszar, K.; Dubus, P.; et al. Lysyl oxidase-like 2 represses notch1 expression in the skin to promote
squamous cell carcinoma progression. EMBO J. 2015, 34, 1090–1109. [CrossRef]
8. Zhang, J.; Yang, R.; Liu, Z.; Hou, C.; Zong, W.; Zhang, A.; Sun, X.; Gao, J. Loss of lysyl oxidase-like 3 causes
cleft palate and spinal deformity in mice. Hum. Mol. Genet. 2015, 24, 6174–6185. [CrossRef]
9. Busnadiego, O.; González-Santamaría, J.; Lagares, D.; Guinea-Viniegra, J.; Pichol-Thievend, C.; Muller, L.;
Rodríguez-Pascual, F. LOXL4 is induced by transforming growth factor β1 through Smad and JunB/Fra2 and
contributes to vascular matrix remodeling. Mol. Cell Biol. 2013, 33, 2388–2401. [CrossRef]
10. Nave, A.H.; Mižíková, I.; Niess, G.; Steenbock, H.; Reichenberger, F.; Talavera, M.L.; Veit, F.; Herold, S.;
Mayer, K.; Vadász, I.; et al. Lysyl oxidases play a causal role in vascular remodeling in clinical and
experimental pulmonary arterial hypertension. Arterioscler. Thromb. Vasc. Biol. 2014, 34, 1446–1458.
[CrossRef]
11. Nordon, I.M.; Hinchliffe, R.J.; Loftus, I.M.; Thompson, M.M. Pathophysiology and epidemiology of abdominal
aortic aneurysms. Nat. Rev. Cardiol. 2011, 8, 92–102. [CrossRef] [PubMed]
12. Brüel, A.; Ortoft, G.; Oxlund, H. Inhibition of cross-links in collagen is associated with reduced stiffness of
the aorta in young rats. Atherosclerosis 1998, 140, 135–145. [CrossRef]
13. Huffman, M.D.; Curci, J.A.; Moore, G.; Kerns, D.B.; Starcher, B.C.; Thompson, R.W. Functional importance of
connective tissue repair during the development of experimental abdominal aortic aneurysms. Surgery 2000,
128, 429–438. [CrossRef] [PubMed]
14. Yoshimura, K.; Aoki, H.; Ikeda, Y.; Fujii, K.; Akiyama, N.; Furutani, A.; Hoshii, Y.; Tanaka, N.; Ricci, R.;
Ishihara, T.; et al. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat.
Med. 2005, 11, 1330–1338. [CrossRef] [PubMed]
15. Remus, E.W.; O’Donnell, R.E.; Rafferty, K.; Weiss, D.; Joseph, G.; Csiszar, K.; Fong, S.F.; Taylor, W.R. The role
of lysyl oxidase family members in the stabilization of abdominal aortic aneurysms. Am. J. Physiol. Heart
Circ. Physiol. 2012, 303, H1067–H1075. [CrossRef] [PubMed]
16. Onoda, M.; Yoshimura, K.; Aoki, H.; Ikeda, Y.; Morikage, N.; Furutani, A.; Matsuzaki, M.; Hamano, K.
Lysyl oxidase resolves inflammation by reducing monocyte chemoattractant protein-1 in abdominal aortic
aneurysm. Atherosclerosis 2010, 208, 366–369. [CrossRef]
17. Mäki, J.M.; Räsänen, J.; Tikkanen, H.; Sormunen, R.; Mäkikallio, K.; Kivirikko, K.I.; Soininen, R. Inactivation
of the lysyl oxidase gene Lox leads to aortic aneurysms, cardiovascular dysfunction, and perinatal death in
mice. Circulation 2002, 106, 2503–2509. [CrossRef]
18. Hornstra, I.K.; Birge, S.; Starcher, B.; Bailey, A.J.; Mecham, R.P.; Shapiro, S.D. Lysyl oxidase is required for
vascular and diaphragmatic development in mice. J. Biol. Chem. 2003, 278, 14387–14393. [CrossRef]
19. Sonesson, B.; Hansen, F.; Länne, T. Abdominal aortic aneurysm: A general defect in the vasculature with
focal manifestations in the abdominal aorta? J. Vasc. Surg. 1997, 26, 247–254. [CrossRef]
Biomolecules 2019, 9, 610 16 of 21
20. Kidholm, C.L.; Beck, H.C.; Madsen, J.B.; Palstrøm, N.B.; Lindholt, J.S.; Rasmussen, L.M. Preliminary analysis
of proteome alterations in non-aneurysmal, internal mammary artery tissue from patients with abdominal
aortic aneurysms. PLoS ONE 2018, 13, e0192957. [CrossRef]
21. Lee, V.S.; Halabi, C.M.; Hoffman, E.P.; Carmichael, N.; Leshchiner, I.; Lian, C.G.; Bierhals, A.J.; Vuzman, D.;
Brigham Genomic Medicine; Mecham, R.P.; et al. Loss of function mutation in LOX causes thoracic aortic
aneurysm and dissection in humans. Proc. Natl. Acad. Sci. USA 2016, 113, 8759–8764. [CrossRef] [PubMed]
22. Guo, D.C.; Regalado, E.S.; Gong, L.; Duan, X.; Santos-Cortez, R.L.; Arnaud, P.; Ren, Z.; Cai, B.; Hostetler, E.M.;
Moran, R.; et al. LOX mutations predispose to thoracic aortic aneurysms and dissections. Circ. Res. 2016,
118, 928–934. [CrossRef] [PubMed]
23. Yu, Y.; Shi, E.; Gu, T.; Tang, R.; Gao, S.; Wang, Y.; Liu, H. Overexpression of microRNA-30a contributes to the
development of aortic dissection by targeting lysyl oxidase. J. Thorac. Cardiovasc. Surg. 2017, 154, 1862–1869.
[CrossRef] [PubMed]
24. Sibon, I.; Sommer, P.; Lamaziere, J.M.; Bonnet, J. Lysyl oxidase deficiency: A new cause of human arterial
dissection. Heart 2005, 91, e33. [CrossRef] [PubMed]
25. Busnadiego, O.; Gorbenko Del Blanco, D.; González-Santamaría, J.; Habashi, J.P.; Calderon, J.F.; Sandoval, P.;
Bedja, D.; Guinea-Viniegra, J.; Lopez-Cabrera, M.; Rosell-Garcia, T.; et al. Elevated expression levels of
lysyl oxidases protect against aortic aneurysm progression in Marfan syndrome. J. Mol. Cell Cardiol. 2015,
85, 48–57. [CrossRef]
26. Aoki, T.; Kataoka, H.; Ishibashi, R.; Nozaki, K.; Morishita, R.; Hashimoto, N. Reduced collagen biosynthesis is
the hallmark of cerebral aneurysm: Contribution of interleukin-1beta and nuclear factor-kappaB. Arterioscler.
Thromb. Vasc. Biol. 2009, 29, 1080–1086. [CrossRef]
27. Akagawa, H.; Narita, A.; Yamada, H.; Tajima, A.; Krischek, B.; Kasuya, H.; Hori, T.; Kubota, M.; Saeki, N.;
Hata, A.; et al. Systematic screening of lysyl oxidase-like (LOXL) family genes demonstrates that LOXL2 is a
susceptibility gene to intracranial aneurysms. Hum. Genet. 2007, 121, 377–387. [CrossRef]
28. Rodríguez, C.; Raposo, B.; Martínez-González, J.; Alcudia, J.F.; Guadall, A.; Badimon, L. Lysyl oxidase
(LOX) expression in the vascular wall: Mechanisms involved in LOX regulation by low density lipoproteins.
Clin. Invest. Arterioscler. 2007, 19, 113–121.
29. Rodriguez, C.; Raposo, B.; Martinez-Gonzalez, J.; Casani, L.; Badimon, L. Low density lipoproteins
down-regulates lysyl oxidase in vascular endothelial cells and the arterial wall. Arterioscler. Thromb. Vasc.
Biol. 2002, 22, 1409–1414. [CrossRef]
30. Raposo, B.; Rodriguez, C.; Martinez-Gonzalez, J.; Badimon, L. High levels of homocysteine inhibit lysyl
oxidase (LOX) and down-regulates LOX expression in vascular endothelial cells. Atherosclerosis 2004, 177, 1–8.
[CrossRef]
31. Rodríguez, C.; Alcudia, J.F.; Martínez-González, J.; Raposo, B.; Navarro, M.A.; Badimon, L. Lysyl oxidase
(LOX) down-regulation by TNFalpha: A new mechanism underlying TNFalpha-induced endothelial
dysfunction. Atherosclerosis 2008, 196, 558–564. [CrossRef] [PubMed]
32. Coral, K.; Angayarkanni, N.; Gomathy, N.; Bharathselvi, M.; Pukhraj, R.; Rupak, R. Homocysteine levels in
the vitreous of proliferative diabetic retinopathy and rhegmatogenous retinal detachment: Its modulating
role on lysyl oxidase. Invest. Ophthalmol. Vis. Sci. 2009, 50, 3607–3612. [CrossRef] [PubMed]
33. Thaler, R.; Agsten, M.; Spitzer, S.; Paschalis, E.P.; Karlic, H.; Klaushofer, K.; Varga, F. Homocysteine suppresses
the expression of the collagen cross-linker lysyl oxidase involving IL-6, Fli1, and epigenetic DNA methylation.
J. Biol. Chem. 2011, 286, 5578–5588. [CrossRef] [PubMed]
34. Rodríguez, C.; Alcudia, J.F.; Martínez-González, J.; Guadall, A.; Raposo, B.; Sánchez-Gómez, S.; Badimon, L.
Statins normalize vascular lysyl oxidase down-regulation induced by proatherogenic risk factors. Cardiovasc.
Res. 2009, 83, 595–603. [CrossRef]
35. Adamopoulos, C.; Piperi, C.; Gargalionis, A.N.; Dalagiorgou, G.; Spilioti, E.; Korkolopoulou, P.;
Diamanti-Kandarakis, E.; Papavassiliou, A.G. Advanced glycation end products upregulate lysyl oxidase
and endothelin-1 in human aortic endothelial cells via parallel activation of ERK1/2-NF-κB and JNK-AP-1
signaling pathways. Cell Mol. Life. Sci. 2016, 73, 1685–1698. [CrossRef]
36. Chvapil, M.; Stith, P.L.; Tillema, L.M.; Carlson, E.C.; Campbell, J.B.; Eskelson, C.D. Early changes in the
arterial wall of chickens fed a cholesterol diet. Atherosclerosis 1976, 24, 393–405. [CrossRef]
37. Kagan, H.M.; Raghavan, J.; Hollander, W. Changes in aortic lysyl oxidase activity in diet-induced
atherosclerosis in the rabbit. Arteriosclerosis 1981, 1, 287–291. [CrossRef]
Biomolecules 2019, 9, 610 17 of 21
38. Kothapalli, D.; Liu, S.L.; Bae, Y.H.; Monslow, J.; Xu, T.; Hawthorne, E.A.; Byfield, F.J.; Castagnino, P.; Rao, S.;
Rader, D.J.; et al. Cardiovascular protection by ApoE and ApoE-HDL linked to suppression of ECM gene
expression and arterial stiffening. Cell Rep. 2012, 2, 1259–1271. [CrossRef]
39. Jover, E.; Silvente, A.; Marín, F.; Martínez-González, J.; Orriols, M.; Martinez, C.M.; Puche, C.M.; Valdés, M.;
Rodriguez, C.; Hernández-Romero, D. Inhibition of enzymes involved in collagen cross-linking reduces
vascular smooth muscle cell calcification. FASEB J. 2018, 32, 4459–4469. [CrossRef]
40. Yamauchi, M.; Sricholpech, M. Lysine post-translational modifications of collagen. Essays Biochem. 2012,
52, 113–133. [CrossRef]
41. Ovchinnikova, O.A.; Folkersen, L.; Persson, J.; Lindeman, J.H.; Ueland, T.; Aukrust, P.; Gavrisheva, N.;
Shlyakhto, E.; Paulsson-Berne, G.; Hedin, U.; et al. The collagen cross-linking enzyme lysyl oxidase is
associated with the healing of human atherosclerotic lesions. J. Intern. Med. 2014, 276, 525–536. [CrossRef]
[PubMed]
42. Butticè, G.; Miller, J.; Wang, L.; Smith, B.D. Interferon-gamma induces major histocompatibility class II
transactivator (CIITA), which mediates collagen repression and major histocompatibility class II activation
by human aortic smooth muscle cells. Circ. Res. 2006, 98, 472–479. [CrossRef] [PubMed]
43. Song, Y.L.; Ford, J.W.; Gordon, D.; Shanley, C.J. Regulation of lysyl oxidase by interferon-gamma in rat aortic
smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 2000, 20, 982–988. [CrossRef] [PubMed]
44. Ovchinnikova, O.; Robertson, A.K.; Wågsäter, D.; Folco, E.J.; Hyry, M.; Myllyharju, J.; Eriksson, P.; Libby, P.;
Hansson, G.K. T-cell activation leads to reduced collagen maturation in atherosclerotic plaques of Apoe(-/-)
mice. Am. J. Pathol. 2009, 174, 693–700. [CrossRef]
45. Ovchinnikova, O.; Gylfe, A.; Bailey, L.; Nordström, A.; Rudling, M.; Jung, C.; Bergström, S.; Waldenström, A.;
Hansson, G.K.; Nordström, P. Osteoprotegerin promotes fibrous cap formation in atherosclerotic lesions of
ApoE-deficient mice—Brief report. Arterioscler. Thromb. Vasc. Biol. 2009, 29, 1478–1480. [CrossRef]
46. Guadall, A.; Orriols, M.; Alcudia, J.F.; Cachofeiro, V.; Martinez-Gonzalez, J.; Rodriguez, C. Hypoxia-induced
ROS signaling is required for LOX up-regulation in endothelial cells. Front. Biosci. 2011, 3, 955–967.
[CrossRef]
47. Matsuura, S.; Mi, R.; Koupenova, M.; Eliades, A.; Patterson, S.; Toselli, P.; Thon, J.; Italiano, J.E., Jr.;
Trackman, P.C.; Papadantonakis, N.; et al. Lysyl oxidase is associated with increased thrombosis and platelet
reactivity. Blood 2016, 127, 1493–1501. [CrossRef]
48. Mäki, J.M.; Sormunen, R.; Lippo, S.; Kaarteenaho-Wiik, R.; Soininen, R.; Myllyharju, J. Lysyl oxidase is
essential for normal development and function of the respiratory system and for the integrity of elastic and
collagen fibers in various tissues. Am. J. Pathol. 2005, 167, 927–936. [CrossRef]
49. Gacheru, S.N.; Thomas, K.M.; Murray, S.A.; Csiszar, K.; Smith-Mungo, L.I.; Kagan, H.M. Transcriptional and
post-transcriptional control of lysyl oxidase expression in vascular smooth muscle cells: Effects of TGF-beta 1
and serum deprivation. J. Cell Biochem. 1997, 65, 395–407. [CrossRef]
50. Green, R.S.; Lieb, M.E.; Weintraub, A.S.; Gacheru, S.N.; Rosenfield, C.L.; Shah, S.; Kagan, H.M.; Taubman, M.B.
Identification of lysyl oxidase and other platelet-derived growth factor-inducible genes in vascular smooth
muscle cells by differential screening. Lab. Invest. 1995, 73, 476–482.
51. Qi, Y.X.; Jiang, J.; Jiang, X.H.; Wang, X.D.; Ji, S.Y.; Han, Y.; Long, D.K.; Shen, B.R.; Yan, Z.Q.; Chien, S.; et al.
PDGF-BB and TGF-{beta}1 on cross-talk between endothelial and smooth muscle cells in vascular remodeling
induced by low shear stress. Proc. Natl. Acad. Sci. USA 2011, 108, 1908–1913. [CrossRef] [PubMed]
52. Martínez, E.; Rodríguez, C.; Miana, M.; Jurado-López, R.; Bartolomé, M.V.; Luaces, M.; Islas, F.;
Martínez-González, J.; López-Andrés, N.; Cachofiero, V. The lysyl oxidase inhibitor β-aminopropionitrile
reduces leptin profibrotic effects and ameliorates cardiovascular remodeling in diet-induced obesity in rats.
J. Mol. Cell Cardiol. 2016, 92, 96–104. [CrossRef] [PubMed]
53. Atsawasuwan, P.; Mochida, Y.; Katafuchi, M.; Kaku, M.; Fong, K.S.; Csiszar, K.; Yamauchi, M. Lysyl oxidase
binds transforming growth factor-beta and regulates its signaling via amine oxidase activity. J. Biol. Chem.
2008, 283, 34229–34240. [CrossRef]
54. Weissen-Plenz, G.; Eschert, H.; Volker, W.; Sindermann, J.R.; Beissert, S.; Robenek, H.; Scheld, H.H.;
Breithardt, G. Granulocyte macrophage colony-stimulating factor deficiency affects vascular elastin
production and integrity of elastic lamellae. J. Vasc. Res. 2008, 45, 103–110. [CrossRef]
55. Lucero, H.A.; Kagan, H.M. Lysyl oxidase: An oxidative enzyme and effector of cell function. Cell Mol. Life Sci.
2006, 63, 2304–2316. [CrossRef] [PubMed]
Biomolecules 2019, 9, 610 18 of 21
56. Li, W.; Liu, G.; Chou, I.N.; Kagan, H.M. Hydrogen peroxide-mediated, lysyl oxidase-dependent chemotaxis
of vascular smooth muscle cells. J. Cell Biochem. 2000, 78, 550–557. [CrossRef]
57. Lucero, H.A.; Ravid, K.; Grimsby, J.L.; Rich, C.B.; DiCamillo, S.J.; Mäki, J.M.; Myllyharju, J.; Kagan, H.M.
Lysyl oxidase oxidizes cell membrane proteins and enhances the chemotactic response of vascular smooth
muscle cells. J. Biol. Chem. 2008, 283, 24103–24117. [CrossRef]
58. Johnson, C.D.; Balagurunathan, Y.; Dougherty, E.R.; Afshari, C.A.; He, Q.; Ramos, K.S. Insight into
redox-regulated gene networks in vascular cells. Bioinformation 2007, 1, 379–383. [CrossRef]
59. Nuthakki, V.K.; Fleser, P.S.; Malinzak, L.E.; Seymour, M.L.; Callahan, R.E.; Bendick, P.J.; Zelenock, G.B.;
Shanley, C.J. Lysyl oxidase expression in a rat model of arterial balloon injury. J. Vasc. Surg. 2004, 40, 123–129.
[CrossRef]
60. Brasselet, C.; Durand, E.; Addad, F.; Al Haj Zen, A.; Smeets, M.B.; Laurent-Maquin, D.; Bouthors, S.; Bellon, G.;
de Kleijn, D.; Godeau, G.; et al. Collagen and elastin cross-linking: A mechanism of constrictive remodeling
after arterial injury. Am. J. Physiol. Heart Circ. Physiol. 2005, 289, H2228–H2233. [CrossRef]
61. Hurtado, P.A.; Vora, S.; Sume, S.S.; Yang, D.; St Hilaire, C.; Guo, Y.; Palamakumbura, A.H.; Schreiber, B.M.;
Ravid, K.; Trackman, P.C. Lysyl oxidase propeptide inhibits smooth muscle cell signaling and proliferation.
Biochem. Biophys. Res. Commun. 2008, 366, 156–161. [CrossRef] [PubMed]
62. Orriols, M.; Guadall, A.; Galán, M.; Martí-Pàmies, I.; Varona, S.; Rodríguez-Calvo, R.; Briones, A.M.;
Navarro, M.A.; de Diego, A.; Osada, J.; et al. Lysyl oxidase (LOX) in vascular remodelling. Insight from a
new animal model. Thromb. Haemost. 2014, 112, 812–824. [CrossRef] [PubMed]
63. Varona, S.; Orriols, M.; Galan, M.; Cañes, L.; Aguilo, S.; Sirvent, M.; Martínez-González, J.; Rodríguez, C.
Lysyl oxidase (LOX) limits VSMC proliferation and neointimal thickening through its extracellular enzymatic
activity. Sci. Rep. 2018, 8, 13258. [CrossRef] [PubMed]
64. Li, W.; Nellaiappan, K.; Strassmaier, T.; Graham, L.; Thomas, K.M.; Kagan, H.M. Localization and activity of
lysyl oxidase within nuclei of fibrogenic cells. Proc. Natl. Acad. Sci. USA 1997, 94, 12817–12822. [CrossRef]
[PubMed]
65. Nellaiappan, K.; Risitano, A.; Liu, G.; Nicklas, G.; Kagan, H.M. Fully processed lysyl oxidase catalyst
translocates from the extracellular space into nuclei of aortic smooth-muscle cells. J. Cell Biochem. 2000,
79, 576–582. [CrossRef]
66. Giampuzzi, M.; Botti, G.; Di Duca, M.; Arata, L.; Ghiggeri, G.; Gusmano, R.; Ravazzolo, R.; Di Donato, A.
Lysyl oxidase activates the transcription activity of human collagene III promoter. Possible involvement of
Ku antigen. J. Biol. Chem. 2000, 275, 36341–36349. [CrossRef]
67. Giampuzzi, M.; Oleggini, R.; Di Donato, A. Demonstration of in vitro interaction between tumor suppressor
lysyl oxidase and histones H1 and H2: Definition of the regions involved. Biochim. Biophys. Acta 2003,
1647, 245–251. [CrossRef]
68. Oleggini, R.; Gastaldo, N.; Di Donato, A. Regulation of elastin promoter by lysyl oxidase and growth factors:
Cross control of lysyl oxidase on TGF-beta1 effects. Matrix Biol. 2007, 26, 494–505. [CrossRef]
69. Saad, F.A.; Torres, M.; Wang, H.; Graham, L. Intracellular lysyl oxidase: Effect of a specific inhibitor on
nuclear mass in proliferating cells. Biochem. Biophys. Res. Commun. 2010, 396, 944–999. [CrossRef]
70. Detrano, R.; Guerci, A.D.; Carr, J.J.; Bild, D.E.; Burke, G.; Folsom, A.R.; Liu, K.; Shea, S.; Szklo, M.;
Bluemke, D.A.; et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups.
N. Engl. J. Med. 2008, 358, 1336–1345. [CrossRef]
71. Peters, S.A.; Bakker, M.; den Ruijter, H.M.; Bots, M.L. Added value of CAC in risk stratification for
cardiovascular events: A systematic review. Eur. J. Clin. Invest. 2012, 42, 110–116. [CrossRef] [PubMed]
72. Greenland, P.; LaBree, L.; Azen, S.P.; Doherty, T.M.; Detrano, R.C. Coronary artery calcium score combined
with Framingham score for risk prediction in asymptomatic individuals. JAMA 2004, 291, 210–215. [CrossRef]
[PubMed]
73. Sugitani, H.; Wachi, H.; Mecham, R.P.; Seyama, Y. Accelerated calcification represses the expression of elastic
fiber components and lysyl oxidase in cultured bovine aortic smooth muscle cells. J. Atheroscler. Thromb.
2002, 9, 292–298. [CrossRef] [PubMed]
74. Hutson, H.N.; Marohl, T.; Anderson, M.; Eliceiri, K.; Campagnola, P.; Masters, K.S. Calcific aortic valve
disease is associated with layer-specific alterations in collagen architecture. PLoS ONE 2016, 11, e0163858.
[CrossRef] [PubMed]
Biomolecules 2019, 9, 610 19 of 21
75. Willum-Hansen, T.; Staessen, J.A.; Torp-Pedersen, C.; Rasmussen, S.; Thijs, L.; Ibsen, H.; Jeppesen, J. Prognostic
value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006,
113, 664–670. [CrossRef] [PubMed]
76. Laurent, S.; Cockcroft, J.; Van Bortel, L.; Boutouyrie, P.; Giannattasio, C.; Hayoz, D.; Pannier, B.;
Vlachopoulos, C.; Wilkinson, I.; Struijker-Boudier, H. European Network for Non-invasive Investigation
of Large Arteries. Expert consensus document on arterial stiffness: Methodological issues and clinical
applications. Eur. Heart J. 2006, 27, 2588–2605. [CrossRef] [PubMed]
77. Mitchell, G.F. Arterial stiffness and hypertension: Chicken or egg? Hypertension 2014, 64, 210–214. [CrossRef]
78. Martínez-Revelles, S.; García-Redondo, A.B.; Avendaño, M.S.; Varona, S.; Palao, T.; Orriols, M.; Roque, F.R.;
Fortuño, A.; Touyz, R.M.; Martínez-González, J.; et al. Lysyl oxidase induces vascular oxidative stress and
contributes to arterial stiffness and abnormal elastin structure in hypertension: Role of p38MAPK. Antioxid.
Redox Signal. 2017, 27, 379–397. [CrossRef]
79. González, J.M.; Briones, A.M.; Starcher, B.; Conde, M.V.; Somoza, B.; Daly, C.; Vila, E.; McGrath, I.;
González, M.C.; Arribas, S.M. Influence of elastin on rat small artery mechanical properties. Exp. Physiol.
2005, 90, 463–468. [CrossRef]
80. Eberson, L.S.; Sanchez, P.A.; Majeed, B.A.; Tawinwung, S.; Secomb, T.W.; Larson, D.F. Effect of lysyl oxidase
inhibition on angiotensin II-induced arterial hypertension, remodeling, and stiffness. PLoS ONE 2015,
10, e0124013. [CrossRef]
81. Staiculescu, M.C.; Kim, J.; Mecham, R.P.; Wagenseil, J.E. Mechanical behavior and matrisome gene expression
in the aneurysm-prone thoracic aorta of newborn lysyl oxidase knockout mice. Am. J. Physiol. Heart
Circ. Physiol. 2017, 313, H446–H456. [CrossRef] [PubMed]
82. Levy, D.; Larson, M.G.; Benjamin, E.J.; Newton-Cheh, C.; Wang, T.J.; Hwang, S.J.; Vasan, R.S.; Mitchell, G.F.
Framingham heart study 100K project: Genome-Wide associations for blood pressure and arterial stiffness.
BMC Med. Genet. 2007, 8, S3. [CrossRef] [PubMed]
83. Steppan, J.; Wang, H.; Bergman, Y.; Rauer, M.J.; Tan, S.; Jandu, S.; Nandakumar, K.; Barreto-Ortiz, S.;
Cole, R.N.; Boronina, T.N.; et al. Lysyl oxidase-like 2 depletion is protective in age-associated vascular
stiffening. Am. J. Physiol. Heart Circ. Physiol. 2019, 317, H49–H59. [CrossRef] [PubMed]
84. Qiu, H.; Zhu, Y.; Sun, Z.; Trzeciakowski, J.P.; Gansner, M.; Depre, C.; Resuello, R.R.; Natividad, F.F.;
Hunter, W.C.; Genin, G.M.; et al. Short communication: Vascular smooth muscle cell stiffness as a mechanism
for increased aortic stiffness with aging. Circ. Res. 2010, 107, 615–619. [CrossRef] [PubMed]
85. Bignon, M.; Pichol-Thievend, C.; Hardouin, J.; Malbouyres, M.; Bréchot, N.; Nasciutti, L.; Barret, A.; Teillon, J.;
Guillon, E.; Etienne, E.; et al. Lysyl oxidase-like protein-2 regulates sprouting angiogenesis and type IV
collagen assembly in the endothelial basement membrane. Blood 2011, 118, 3979–3989. [CrossRef] [PubMed]
86. Del Toro, R.; Prahst, C.; Mathivet, T.; Siegfried, G.; Kaminker, J.S.; Larrivee, B.; Breant, C.; Duarte, A.;
Takakura, N.; Fukamizu, A.; et al. Identification and functional analysis of endothelial tip cell-enriched
genes. Blood 2010, 116, 4025–4033. [CrossRef]
87. De Jong, O.G.; van der Waals, L.M.; Kools, F.R.W.; Verhaar, M.C.; van Balkom, B.W.M. Lysyl oxidase-like 2 is
a regulator of angiogenesis through modulation of endothelial-to-mesenchymal transition. J. Cell Physiol.
2019, 234, 10260–10269. [CrossRef]
88. Zaffryar-Eilot, S.; Marshall, D.; Voloshin, T.; Bar-Zion, A.; Spangler, R.; Kessler, O.; Ghermazien, H.;
Brekhman, V.; Suss-Toby, E.; Adam, D.; et al. Lysyl oxidase-like-2 promotes tumour angiogenesis and is a
potential therapeutic target in angiogenic tumours. Carcinogenesis 2013, 34, 2370–2379. [CrossRef]
89. Barry-Hamilton, V.; Spangler, R.; Marshall, D.; McCauley, S.; Rodriguez, H.M.; Oyasu, M.; Mikels, A.;
Vaysberg, M.; Ghermazien, H.; Wai, C.; et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the
development of a pathologic microenvironment. Nat. Med. 2010, 16, 1009–1017. [CrossRef]
90. Chang, J.; Lucas, M.C.; Leonte, L.E.; Garcia-Montolio, M.; Singh, L.B.; Findlay, A.D.; Deodhar, M.; Foot, J.S.;
Jarolimek, W.; Timpson, P.; et al. Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer.
Oncotarget 2017, 8, 26066–26078. [CrossRef]
91. Baker, A.M.; Bird, D.; Welti, J.C.; Gourlaouen, M.; Lang, G.; Murray, G.I.; Reynolds, A.R.; Cox, T.R.; Erler, J.T.
Lysyl oxidase plays a critical role in endothelial cell stimulation to drive tumor angiogenesis. Cancer Res.
2013, 73, 583–594. [CrossRef] [PubMed]
Biomolecules 2019, 9, 610 20 of 21
92. Osawa, T.; Ohga, N.; Akiyama, K.; Hida, Y.; Kitayama, K.; Kawamoto, T.; Yamamoto, K.; Maishi, N.;
Kondoh, M.; Onodera, Y.; et al. Lysyl oxidase secreted by tumour endothelial cells promotes angiogenesis
and metastasis. Br. J. Cancer. 2013, 109, 2237–2247. [CrossRef] [PubMed]
93. Rossow, L.; Veitl, S.; Vorlová, S.; Wax, J.K.; Kuhn, A.E.; Maltzahn, V.; Upcin, B.; Karl, F.; Hoffmann, H.;
Gätzner, S.; et al. LOX-catalyzed collagen stabilization is a proximal cause for intrinsic resistance to
chemotherapy. Oncogene 2018, 37, 4921–4940. [CrossRef] [PubMed]
94. Nareshkumar, R.N.; Sulochana, K.N.; Coral, K. Inhibition of angiogenesis in endothelial cells by human lysyl
oxidase propeptide. Sci. Rep. 2018, 8, 10426. [CrossRef]
95. Li, R.; Wang, Y.; Zhang, X.; Feng, M.; Ma, J.; Li, J.; Yang, X.; Fang, F.; Xia, Q.; Zhang, Z.; et al. Exosome-mediated
secretion of LOXL4 promotes hepatocellular carcinoma cell invasion and metastasis. Mol. Cancer. 2019,
18, 18. [CrossRef]
96. Kucharzewska, P.; Christianson, H.C.; Welch, J.E.; Svensson, K.J.; Fredlund, E.; Ringnér, M.; Mörgelin, M.;
Bourseau-Guilmain, E.; Bengzon, J.; Belting, M. Exosomes reflect the hypoxic status of glioma cells and
mediate hypoxia-dependent activation of vascular cells during tumor development. Proc. Natl. Acad.
Sci. USA 2013, 110, 7312–7317. [CrossRef]
97. Kore, R.A.; Edmondson, J.L.; Jenkins, S.V.; Jamshidi-Parsian, A.; Dings, R.P.M.; Reyna, N.S.; Griffin, R.J.
Hypoxia-derived exosomes induce putative altered pathways in biosynthesis and ion regulatory channels in
glioblastoma cells. Biochem. Biophys. Rep. 2018, 14, 104–113. [CrossRef]
98. González-Santamaría, J.; Villalba, M.; Busnadiego, O.; López-Olañeta, M.M.; Sandoval, P.; Snabel, J.;
López-Cabrera, M.; Erler, J.T.; Hanemaaijer, R.; Lara-Pezzi, E.; et al. Matrix cross-linking lysyl oxidases
are induced in response to myocardial infarction and promote cardiac dysfunction. Cardiovasc. Res. 2016,
109, 67–78. [CrossRef]
99. Badenhorst, D.; Maseko, M.; Tsotetsi, O.J.; Naidoo, A.; Brooksbank, R.; Norton, G.R.; Woodiwiss, A.J.
Cross-linking influences the impact of quantitative changes inmyocardial collagen on cardiac stiffness and
remodelling in hypertension in rats. Cardiovasc. Res. 2003, 57, 632–641. [CrossRef]
100. Stefanon, I.; Valero-Muñoz, M.; Fernandes, A.A.; Ribeiro, R.F., Jr.; Rodríguez, C.; Miana, M.;
Martínez-González, J.; Spalenza, J.S.; Lahera, V.; Vassallo, P.F.; et al. Left and right ventricle late remodeling
following myocardial infarction in rats. PLoS ONE 2013, 8, e64986. [CrossRef]
101. Norton, G.R.; Tsotetsi, J.; Trifunovic, B.; Hartford, C.; Candy, G.P.; Woodiwiss, A.J. Myocardial stiffness is
attributed to alterations in cross-linked collagen rather than total collagen or phenotypes in spontaneously
hypertensive rats. Circulation 1997, 96, 1991–1998. [CrossRef] [PubMed]
102. López, B.; Querejeta, R.; González, A.; Larman, M.; Díez, J. Collagen cross-linking but not collagen amount
associates with elevated filling pressures in hypertensive patients with stage C heart failure: Potential role of
lysyl oxidase. Hypertension 2012, 60, 677–683. [CrossRef] [PubMed]
103. Kasner, M.; Westermann, D.; Lopez, B.; Gaub, R.; Escher, F.; Kühl, U.; Schultheiss, H.P.; Tschöpe, C. Diastolic
tissue Doppler indexes correlate with the degree of collagen expression and crosslinking in heart failure and
normal ejection fraction. J. Am. Coll. Cardiol. 2011, 57, 977–985. [CrossRef] [PubMed]
104. Galán, M.; Varona, S.; Guadall, A.; Orriols, M.; Navas, M.; Aguiló, S.; de Diego, A.; Navarro, M.A.;
García-Dorado, D.; Rodríguez-Sinovas, A.; et al. Lysyl oxidase over-expression accelerates cardiac
remodelling and aggravates angiotensin II-induced hypertrophy. FASEB J. 2017, 31, 3787–3799. [CrossRef]
[PubMed]
105. Yang, J.; Savvatis, K.; Kang, J.S.; Fan, P.; Zhong, H.; Schwartz, K.; Barry, V.; Mikels-Vigdal, A.; Karpinski, S.;
Kornyeyev, D.; et al. Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment. Nat. Commun.
2016, 7, 13710. [CrossRef]
106. Van Putten, S.; Shafieyan, Y.; Hinz, B. Mechanical control of cardiac myofibroblasts. J. Mol. Cell Cardiol. 2016,
93, 133–142. [CrossRef]
107. Voloshenyuk, T.G.; Landesman, E.S.; Khoutorova, E.; Hart, A.D.; Gardner, J.D. Induction of cardiac fibroblast
lysyl oxidase by TGF-β1 requires PI3K/Akt, Smad3, and MAPK signaling. Cytokine 2011, 55, 90–97. [CrossRef]
108. Lu, M.; Qin, Q.; Yao, J.; Sun, L.; Qin, X. Induction of LOX by TGF-β1/Smad/AP-1 signaling aggravates rat
myocardial fibrosis and heart failure. IUBMB Life 2019. [CrossRef]
109. Kubota, T.; McTiernan, C.F.; Frye, C.S.; Slawson, S.E.; Lemster, B.H.; Koretsky, A.P.; Demetris, A.J.;
Feldman, A.M. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor
necrosis factor-alpha. Circ. Res. 1997, 81, 627–635. [CrossRef]
Biomolecules 2019, 9, 610 21 of 21
110. Voloshenyuk, T.G.; Hart, A.D.; Khoutorova, E.; Gardner, J.D. TNF-α increases cardiac fibroblast lysyl oxidase
expression through TGF-β and PI3Kinase signaling pathways. Biochem. Biophys. Res. Commun. 2011,
413, 370–375. [CrossRef]
111. López, B.; González, A.; Lindner, D.; Westermann, D.; Ravassa, S.; Beaumont, J.; Gallego, I.; Zudaire, A.;
Brugnolaro, C.; Querejeta, R.; et al. Osteopontin-mediated myocardial fibrosis in heart failure: A role for
lysyl oxidase? Cardiovasc. Res. 2013, 99, 111–120. [CrossRef] [PubMed]
112. Yu, Q.; Vazquez, R.; Zabadi, S.; Watson, R.R.; Larson, D.F. T-lymphocytes mediate left ventricular fibrillar
collagen cross-linking and diastolic dysfunction in mice. Matrix Biol. 2010, 29, 511–518. [CrossRef] [PubMed]
113. Ahsan, T.; Lottman, L.M.; Harwood, F.; Amiel, D.; Sah, R.L. Integrative cartilage repair: Inhibition by
beta-aminopropionitrile. J. Orthop. Res. 1999, 17, 850–857. [CrossRef] [PubMed]
114. Spencer, P.S.; Schaumburg, H.H. Lathyrism: A neurotoxic disease. Neurobehav. Toxicol. Teratol. 1983,
5, 625–629. [PubMed]
115. Turecek, C.; Fratzl-Zelman, N.; Rumpler, M.; Buchinger, B.; Spitzer, S.; Zoehrer, R.; Durchschlag, E.;
Klaushofer, K.; Paschalis, E.P.; Varga, F. Collagen cross-linking influences osteoblastic differentiation.
Calcif. Tissue Int. 2008, 82, 392–400. [CrossRef] [PubMed]
116. Dasler, W. Isolation of toxic crystals from sweet peas (Lathyrus odoratus). Science 1954, 120, 307–308. [CrossRef]
[PubMed]
117. Fickert, P. Is this the last requiem for Simtuzumab? Hepatology 2019, 69, 476–479. [CrossRef]
118. Rowbottom, M.W.; Bain, G.; Calderon, I.; Lasof, T.; Lonergan, D.; Lai, A.; Huang, F.; Darlington, J.;
Prodanovich, P.; Santini, A.M.; et al. Identification of 4-(aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)
pyridine derivatives as potent, selective, and orally efficacious inhibitors of the copper-dependent amine
oxidase, lysyl oxidase-like 2 (LOXL2). J. Med. Chem. 2017, 60, 4403–4423. [CrossRef]
119. López, B.; Querejeta, R.; González, A.; Beaumont, J.; Larman, M.; Díez, J. Impact of treatment on myocardial
lysyl oxidase expression and collagen cross-linking in patients with heart failure. Hypertension 2009,
53, 236–242. [CrossRef]
120. Miguel-Carrasco, J.L.; Beaumont, J.; San José, G.; Moreno, M.U.; López, B.; González, A.; Zalba, G.; Díez, J.;
Fortuño, A.; Ravassa, S. Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites.
Sci. Rep. 2017, 7, 41865. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
